Vivos Therapeutics, Inc. (NASDAQ:VVOS) Receives $4.92 Average Price Target from Brokerages

Shares of Vivos Therapeutics, Inc. (NASDAQ:VVOS) have been given an average rating of “Hold” by the five ratings firms that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $4.9167.

VVOS has been the topic of several research reports. Ascendiant Capital Markets dropped their target price on shares of Vivos Therapeutics from $6.50 to $5.50 and set a “buy” rating on the stock in a report on Wednesday, December 3rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Vivos Therapeutics in a research note on Wednesday, January 21st. Finally, Zacks Research raised Vivos Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, December 1st.

Institutional Trading of Vivos Therapeutics

Hedge funds have recently bought and sold shares of the company. XTX Topco Ltd bought a new stake in shares of Vivos Therapeutics during the 2nd quarter valued at $65,000. B. Riley Wealth Advisors Inc. bought a new position in Vivos Therapeutics in the 2nd quarter worth $220,000. Connective Capital Management LLC purchased a new position in Vivos Therapeutics during the third quarter valued at $620,000. Acorn Wealth Advisors LLC bought a new stake in Vivos Therapeutics during the fourth quarter valued at about $30,000. Finally, DRW Securities LLC grew its holdings in Vivos Therapeutics by 179.5% during the fourth quarter. DRW Securities LLC now owns 115,907 shares of the company’s stock valued at $235,000 after purchasing an additional 74,441 shares during the period. Hedge funds and other institutional investors own 26.35% of the company’s stock.

Vivos Therapeutics Stock Performance

Shares of VVOS stock opened at $1.19 on Friday. The company has a quick ratio of 0.78, a current ratio of 0.78 and a debt-to-equity ratio of 3.31. The company has a 50 day moving average price of $1.52 and a 200-day moving average price of $2.23. Vivos Therapeutics has a 52 week low of $1.09 and a 52 week high of $7.95. The firm has a market capitalization of $12.46 million, a PE ratio of -0.67 and a beta of 6.94.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.